These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20865737)

  • 1. A qualitative study of the ramifications of rash from epidermal growth factor receptor (EGFR) inhibitors.
    Coleman S; Kovtun I; Nguyen PL; Pittelkow M; Jatoi A
    Psychooncology; 2011 Nov; 20(11):1246-9. PubMed ID: 20865737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
    Yalici-Armagan B; Ayanoglu BT; Demirdag HG
    Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
    [No Abstract]   [Full Text] [Related]  

  • 3. Does sunscreen prevent epidermal growth factor receptor (EGFR) inhibitor-induced rash? Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N05C4).
    Jatoi A; Thrower A; Sloan JA; Flynn PJ; Wentworth-Hartung NL; Dakhil SR; Mattar BI; Nikcevich DA; Novotny P; Sekulic A; Loprinzi CL
    Oncologist; 2010; 15(9):1016-22. PubMed ID: 20798191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rash management and treatment persistence of cancer patients treated with epidermal growth factor receptor inhibitors in the Truven MarketScan
    Chen L; Brown J; Marmaduke DQ; Mayo C; Grau G; Lau YK; Obasaju CK
    Support Care Cancer; 2018 Jul; 26(7):2369-2377. PubMed ID: 29423677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors.
    Wong SF; Lindgren A; Mummaneni M; Byun T; Vasko C; Arenos R; Alexson E; Osann K
    J Support Oncol; 2010; 8(5):202-8. PubMed ID: 21086877
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adapalene Gel 0.1% Versus Placebo as Prophylaxis for Anti-Epidermal Growth Factor Receptor-Induced Acne-Like Rash: A Randomized Left-Right Comparative Evaluation (APPEARANCE).
    Chayahara N; Mukohara T; Tachihara M; Fujishima Y; Fukunaga A; Washio K; Yamamoto M; Nakata K; Kobayashi K; Takenaka K; Toyoda M; Kiyota N; Tobimatsu K; Doi H; Mizuta N; Marugami N; Kawaguchi A; Nishigori C; Nishimura Y; Minami H
    Oncologist; 2019 Jul; 24(7):885-e413. PubMed ID: 30890624
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor (EGFR) inhibitor-induced rash: a consecutive patient series that illustrates the need for rigorous palliative trials.
    Solomon BM; Jatoi A
    J Palliat Med; 2011 Feb; 14(2):153-6. PubMed ID: 21226620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prophylactic Topical Treatment for EGFR Inhibitor-Induced Papulopustular Rash: A Randomized Clinical Trial.
    Amitay-Laish I; Prag-Naveh H; Ollech A; Davidovici B; Leshem YA; Snast I; Popovtzer A; Purim O; Flex D; David M; Brenner B; Ben-Aharon I; Peled N; Hodak E; Stemmer SM
    Dermatology; 2021; 237(6):988-994. PubMed ID: 33378750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Androgen Mediation-and Antiandrogens Mitigation-of the Epidermal Growth Factor Receptor (EGFR) Inhibitor-Induced Rash: Results From a Pilot Randomized Trial and Small Translational Case Series.
    Le-Rademacher JG; Rowland K; Atherton PJ; Dakhil C; Sun Z; Tan A; Schmidt L; Nguyen PL; Radecki Breitkopf C; Pittelkow M; Tindall D; Menon S; Jatoi A
    Am J Hosp Palliat Care; 2019 Jun; 36(6):519-525. PubMed ID: 30602311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Skin toxicities associated with epidermal growth factor receptor inhibitors.
    Li T; Perez-Soler R
    Target Oncol; 2009 Apr; 4(2):107-19. PubMed ID: 19452131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB).
    Jatoi A; Rowland K; Sloan JA; Gross HM; Fishkin PA; Kahanic SP; Novotny PJ; Schaefer PL; Johnson DB; Tschetter LK; Loprinzi CL
    Cancer; 2008 Aug; 113(4):847-53. PubMed ID: 18543329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical features and treatment of epidermal growth factor inhibitor-related late-phase papulopustular rash.
    Tohyama M; Hamada M; Harada D; Kozuki T; Nogami N; Monden N; Kajiwara T; Nishina T
    J Dermatol; 2020 Feb; 47(2):121-127. PubMed ID: 31803963
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rash from EGFR inhibitors: opportunities and challenges for palliation.
    Solomon BM; Jatoi A
    Curr Oncol Rep; 2008 Jul; 10(4):304-8. PubMed ID: 18778556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rash as a surrogate marker for efficacy of epidermal growth factor receptor inhibitors in lung cancer.
    Perez-Soler R
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S7-14. PubMed ID: 17239291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between epidermal growth factor receptor mutations and skin rash in non-small cell lung cancer patients.
    Tanaka H; Atagi K; Tatsumichi T; Yamaguchi K; Takahashi K; Kaji M; Kosaka S; Houchi H
    J Chemother; 2020 Apr; 32(2):83-87. PubMed ID: 31957595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Skin Toxicities with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Cancer Patients: A Meta-Analysis of Randomized Controlled Trials.
    Sun W; Li J
    Cancer Invest; 2019; 37(6):253-264. PubMed ID: 31303065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Managing dermatologic toxicities of epidermal growth factor receptor inhibitors.
    Chou LS; Garey J; Oishi K; Kim E
    Clin Lung Cancer; 2006 Dec; 8 Suppl 1():S15-22. PubMed ID: 17239286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive blood plasma biomarkers for EGFR inhibitor-induced skin rash.
    Hichert V; Scholl C; Steffens M; Paul T; Schumann C; Rüdiger S; Boeck S; Heinemann V; Kächele V; Seufferlein T; Stingl J
    Oncotarget; 2017 May; 8(21):35193-35204. PubMed ID: 28456787
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Case of Lenalidomide-Associated Papulopustular Rash: Beyond the Epidermal Growth Factor Receptor Inhibitor Spectrum.
    Fernandez-Nieto D; Ortega-Quijano D; Jimenez-Cauhe J; Saceda-Corralo D; Bea-Ardebol S
    Am J Ther; 2020; 27(4):e417-e419. PubMed ID: 32618603
    [No Abstract]   [Full Text] [Related]  

  • 20. Don't jump to rash conclusions.
    Bebb G; Boland W; Melosky B
    Cancer Biol Ther; 2011 Apr; 11(7):639-41. PubMed ID: 21304273
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.